Browsing Tag
Vas Narasimhan
8 posts
Novartis makes $12bn bet on RNA medicine with Avidity Biosciences acquisition to expand rare-disease pipeline
Find out why Novartis’s $12 billion Avidity Biosciences deal marks a turning point for big pharma’s RNA-therapy ambitions.
October 26, 2025
Novartis dodges Trump’s drug tariff blitz with $23bn US reshoring plan
Find out how Novartis plans to produce all key medicines in the US through a $23B investment in 10 new and expanded facilities nationwide.
April 11, 2025
Novartis achieves 22% rise in core operating income, driven by innovative medicines
Novartis has reported a stellar performance for the fourth quarter of 2024, showcasing impressive growth across its core…
February 9, 2025
Novartis acquires kidney disease innovator Chinook Therapeutics
Swiss pharmaceutical giant Novartis has wrapped up the previously announced $3.5 billion acquisition of Seattle-based biopharmaceutical firm Chinook…
August 14, 2023
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington…
June 12, 2023
Novartis gets Leqvio FDA approval for reducing bad cholesterol levels
Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA)…
January 2, 2022
Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for…
April 9, 2018
GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn
In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis’ 36.5% stake in their…
March 28, 2018